The End-of-the-Road for Immunotherapies in GBM or New Opportunities for More Nuanced/aggressive Approaches? CheckMate 498
Published in Brain Cancer4 May 2022
IMO, more like CheckMate trials, GBM game over.
Pre clinical rodent data results looked good, but did not benefit the GBM patients.
https://www.practiceupdate.com/c/135377/67/12/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_braincancer&elsca4=braincancer&elsca5=newsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20849606
Regards.
The End-of-the-Road for Immunotherapies in GBM or New...
Add to My Watchlist
What is My Watchlist?